Drug Trial Radar · NCT07029529
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
May 12, 2026
Primary completion
Aug 2030
Study completion Aug 2030
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
For this protocol, the investigators plan to collect data to evaluate apremilast (60mg/day) vs placebo in adults with Alcohol Use Disorders (AUD).
Conditions
- Alcohol Use Disorder
Interventions
Apremilast 60mgDrug
Apremilast 60mg/day
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alcohol ConsumptionTime frame: Lab Sessions (Days 10, 17 & 24)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.